Nothing Special   »   [go: up one dir, main page]

CA2398861A1 - Methodologies de disruption genique destinees a la decouverte de medicaments cibles - Google Patents

Methodologies de disruption genique destinees a la decouverte de medicaments cibles Download PDF

Info

Publication number
CA2398861A1
CA2398861A1 CA002398861A CA2398861A CA2398861A1 CA 2398861 A1 CA2398861 A1 CA 2398861A1 CA 002398861 A CA002398861 A CA 002398861A CA 2398861 A CA2398861 A CA 2398861A CA 2398861 A1 CA2398861 A1 CA 2398861A1
Authority
CA
Canada
Prior art keywords
gene
cells
seq
nucleotide sequence
genes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002398861A
Other languages
English (en)
Inventor
Terry Roemer
Bo Jiang
Charles Boone
Howard Bussey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2398861A1 publication Critical patent/CA2398861A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C07K14/40—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Candida
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne des procédés et compositions permettant de déterminer de manière expérimentale si un quelconque gène du génome d'un organisme pathogène diploïde est essentiel et s'il est nécessaire à la virulence ou au pouvoir pathogène. Ces procédés consistent à construire des mutants génétiques dans lesquels un allèle d'un gène spécifique est inactivé tandis que l'autre allèle du gène est placé dans des conditions d'éventuelle expression. L'identification de gènes essentiels et de gènes critiques quant au développement d'infections virulentes constitue une base de développement du criblage de nouveaux médicaments dirigés contre ces organismes pathogènes. L'invention concerne encore des gènes <i>Candida albicans</i> qui se sont révélés être essentiels dans le criblage de médicaments et constituent des cibles potentielles à cette fin. On peut utiliser la séquence nucléotidique de ces gènes cibles à des fins de découverte de médicaments, telle que l'expression de la protéine de recombinaison, le dosage d'hybridation et la construction d'ensembles d'acides nucléiques. L'invention concerne enfin l'utilisation de protéines, codées par les gènes essentiels, et de cellules modifiées génétiquement et comprenant des allèles modifiés de gènes essentiels, dans divers procédés de criblage.
CA002398861A 2000-02-18 2001-02-20 Methodologies de disruption genique destinees a la decouverte de medicaments cibles Abandoned CA2398861A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18353400P 2000-02-18 2000-02-18
US60/183,534 2000-02-18
PCT/US2001/005551 WO2001060975A2 (fr) 2000-02-18 2001-02-20 Methodologies de disruption genique destinees a la decouverte de medicaments cibles

Publications (1)

Publication Number Publication Date
CA2398861A1 true CA2398861A1 (fr) 2001-08-23

Family

ID=22673211

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002398861A Abandoned CA2398861A1 (fr) 2000-02-18 2001-02-20 Methodologies de disruption genique destinees a la decouverte de medicaments cibles

Country Status (7)

Country Link
EP (1) EP1292668A2 (fr)
JP (1) JP2003523197A (fr)
KR (1) KR20020097180A (fr)
AU (1) AU2001243204A1 (fr)
CA (1) CA2398861A1 (fr)
NZ (1) NZ521037A (fr)
WO (1) WO2001060975A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030180953A1 (en) * 2000-12-29 2003-09-25 Elitra Pharmaceuticals, Inc. Gene disruption methodologies for drug target discovery
WO2003010333A2 (fr) * 2001-07-24 2003-02-06 Affinium Pharmaceuticals Inc. Methodes de disruption genique et leurs utilisations
WO2003091418A2 (fr) 2002-04-26 2003-11-06 Bristol-Myers Squibb Company Nouveaux polynucleotides fongiques essentiels, polypeptides et techniques d'utilisation
GB0228702D0 (en) * 2002-12-09 2003-01-15 Oxford Glycosciences Uk Ltd Novel therapeutic target
GB0228694D0 (en) * 2002-12-09 2003-01-15 Oxford Glycosciences Uk Ltd Novel threapeutic target
GB0228697D0 (en) * 2002-12-09 2003-01-15 Oxford Glycosciences Uk Ltd Novel therapeutic target
GB0228704D0 (en) * 2002-12-09 2003-01-15 Oxford Glycosciences Uk Ltd Novel therapeutic target
EP1466974A1 (fr) * 2003-04-11 2004-10-13 Max-Delbrück-Centrum Für Molekulare Medizin Mutagenèse dirigé inductible grâce au sauvetage conditionel d'un gène
CN108707554B (zh) * 2018-05-21 2021-06-29 河北省农林科学院植物保护研究所 一对玉蜀黍黑粉菌组合及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824545A (en) * 1995-11-01 1998-10-20 Millennium Pharaceuticals, Inc. Identification of eukaryotic growth-related genes and promoter isolation vector and method of use
CA2218446A1 (fr) * 1997-12-12 1999-06-12 Mcgill University Nouveau candida albicans kre9 et applications
EP1161544A1 (fr) * 1999-03-11 2001-12-12 GPC Biotech Inc. Generation de mutants de levure conditionnels, techniques et reactifs s'y rapportant

Also Published As

Publication number Publication date
AU2001243204A1 (en) 2001-08-27
JP2003523197A (ja) 2003-08-05
NZ521037A (en) 2004-09-24
WO2001060975A2 (fr) 2001-08-23
EP1292668A2 (fr) 2003-03-19
KR20020097180A (ko) 2002-12-31
WO2001060975A3 (fr) 2002-04-25

Similar Documents

Publication Publication Date Title
US20030180953A1 (en) Gene disruption methodologies for drug target discovery
US20030119013A1 (en) Identification of essential genes of Aspergillus fumigatus and methods of use
CA2188950C (fr) Expression fonctionnelle d&#39;adenylyle-cyclase de mammifere dans la levure
US7081360B2 (en) Expression of G protein-coupled receptors with altered ligand binding and/or coupling properties
WO2004067709A2 (fr) Identification de genes essentiels d&#39;aspergillus fumigatus et methodes d&#39;utilisation
US20040014955A1 (en) Identification of essential genes of cryptococcus neoformans and methods of use
CA2398861A1 (fr) Methodologies de disruption genique destinees a la decouverte de medicaments cibles
US6200803B1 (en) Essential genes of yeast as targets for antifungal agents, herbicides, insecticides and anti-proliferative drugs
US20050079619A1 (en) Gene disruption methodologies for drug target discovery
US6280963B1 (en) Essential fungal genes and their use
US20050019931A1 (en) Nucleic acids encoding antifungal drug targets and methods of use
US20030009022A1 (en) Methods and compositions for identifying receptor effectors
EP1173619B1 (fr) Identification de genes specifiques fongiques essentiels de candida albicans et leur utilisation dans la decouverte de medicaments antifongiques
WO1997040170A2 (fr) Expression fonctionnelle d&#39;adenylcyclase heterologue
AU2002231144A1 (en) Gene disruption methodologies for drug target discovery
US6197517B1 (en) Essential genes of yeast as targets for antifungal agents, herbicides, insecticides and anti-proliferative drugs
AU2002254729A1 (en) Identification of essential genes of aspegillus fumigatus and methods of use
US20020103154A1 (en) Essential genes of yeast as targets for antifungal agents, herbicides, insecticides and anti-proliferation drugs
CA2366069A1 (fr) Generation de mutants de levure conditionnels, techniques et reactifs s&#39;y rapportant
Broughton Cloning and characterisation of a SEC61 homologue from Schizosaccharomyces pombe

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued